Extended-interval dosing of natalizumab in NOVA

Lancet Neurol. 2023 Mar;22(3):199-200. doi: 10.1016/S1474-4422(23)00032-7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use
  • Leukoencephalopathy, Progressive Multifocal*
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting*
  • Natalizumab / therapeutic use

Substances

  • Natalizumab
  • Immunologic Factors